Cargando…

Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis

BACKGROUND: The aim of this study was to compare the efficacies of the XELOX and DOS regimens as preoperative chemotherapy in patients with locally advanced gastric cancer. METHODS: All cases of locally advanced gastric cancer treated with the XELOX or DOS regimen were reviewed retrospectively. Prop...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yan, Cheng, Xi, Cui, Yue-hong, Hou, Jun, Ji, Yuan, Sun, Yi-hong, Shen, Zhen-bin, Liu, Feng-lin, Liu, Tian-shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027771/
https://www.ncbi.nlm.nih.gov/pubmed/29954358
http://dx.doi.org/10.1186/s12885-018-4615-z
_version_ 1783336667081342976
author Wang, Yan
Cheng, Xi
Cui, Yue-hong
Hou, Jun
Ji, Yuan
Sun, Yi-hong
Shen, Zhen-bin
Liu, Feng-lin
Liu, Tian-shu
author_facet Wang, Yan
Cheng, Xi
Cui, Yue-hong
Hou, Jun
Ji, Yuan
Sun, Yi-hong
Shen, Zhen-bin
Liu, Feng-lin
Liu, Tian-shu
author_sort Wang, Yan
collection PubMed
description BACKGROUND: The aim of this study was to compare the efficacies of the XELOX and DOS regimens as preoperative chemotherapy in patients with locally advanced gastric cancer. METHODS: All cases of locally advanced gastric cancer treated with the XELOX or DOS regimen were reviewed retrospectively. Propensity score matching (PSM) was carried out to reduce selection bias based on age, gender, location, Lauren type, carcinoembryonic antigen level, clinical tumor stage, and clinical node stage. RESULTS: From January 2010 to December 2016, 248 patients were matched; 159 of them received the XELOX regimen and 89 the DOS regimen. The response rates in the XELOX and DOS groups were 34.5 and 38.1%, respectively (P = 0.823). After four cycles of chemotherapy, 111 patients (69.8%) in the XELOX group and 65 patients (73.0%) in the DOS group underwent radical surgery (P = 0.485). The median progression-free survival (33.0 months vs. 18.7 months, P = 0.0356) and the median overall survival (43.8 months vs. 29.1 months, P = 0.0003) were longer for patients who received the DOS regimen than for those who received the XELOX regimen. The occurrence of grade 3 to 4 toxicity was similar in the two groups. CONCLUSIONS: For locally advanced gastric cancer patients, the DOS regimen showed more benefit than the XELOX regimen as preoperative chemotherapy, without any added toxicity effects.
format Online
Article
Text
id pubmed-6027771
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60277712018-07-09 Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis Wang, Yan Cheng, Xi Cui, Yue-hong Hou, Jun Ji, Yuan Sun, Yi-hong Shen, Zhen-bin Liu, Feng-lin Liu, Tian-shu BMC Cancer Research Article BACKGROUND: The aim of this study was to compare the efficacies of the XELOX and DOS regimens as preoperative chemotherapy in patients with locally advanced gastric cancer. METHODS: All cases of locally advanced gastric cancer treated with the XELOX or DOS regimen were reviewed retrospectively. Propensity score matching (PSM) was carried out to reduce selection bias based on age, gender, location, Lauren type, carcinoembryonic antigen level, clinical tumor stage, and clinical node stage. RESULTS: From January 2010 to December 2016, 248 patients were matched; 159 of them received the XELOX regimen and 89 the DOS regimen. The response rates in the XELOX and DOS groups were 34.5 and 38.1%, respectively (P = 0.823). After four cycles of chemotherapy, 111 patients (69.8%) in the XELOX group and 65 patients (73.0%) in the DOS group underwent radical surgery (P = 0.485). The median progression-free survival (33.0 months vs. 18.7 months, P = 0.0356) and the median overall survival (43.8 months vs. 29.1 months, P = 0.0003) were longer for patients who received the DOS regimen than for those who received the XELOX regimen. The occurrence of grade 3 to 4 toxicity was similar in the two groups. CONCLUSIONS: For locally advanced gastric cancer patients, the DOS regimen showed more benefit than the XELOX regimen as preoperative chemotherapy, without any added toxicity effects. BioMed Central 2018-06-28 /pmc/articles/PMC6027771/ /pubmed/29954358 http://dx.doi.org/10.1186/s12885-018-4615-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wang, Yan
Cheng, Xi
Cui, Yue-hong
Hou, Jun
Ji, Yuan
Sun, Yi-hong
Shen, Zhen-bin
Liu, Feng-lin
Liu, Tian-shu
Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis
title Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis
title_full Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis
title_fullStr Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis
title_full_unstemmed Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis
title_short Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis
title_sort efficacy after preoperative capecitabine and oxaliplatin (xelox) versus docetaxel, oxaliplatin and s1 (dos) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027771/
https://www.ncbi.nlm.nih.gov/pubmed/29954358
http://dx.doi.org/10.1186/s12885-018-4615-z
work_keys_str_mv AT wangyan efficacyafterpreoperativecapecitabineandoxaliplatinxeloxversusdocetaxeloxaliplatinands1dosinpatientswithlocallyadvancedgastricadenocarcinomaapropensityscorematchinganalysis
AT chengxi efficacyafterpreoperativecapecitabineandoxaliplatinxeloxversusdocetaxeloxaliplatinands1dosinpatientswithlocallyadvancedgastricadenocarcinomaapropensityscorematchinganalysis
AT cuiyuehong efficacyafterpreoperativecapecitabineandoxaliplatinxeloxversusdocetaxeloxaliplatinands1dosinpatientswithlocallyadvancedgastricadenocarcinomaapropensityscorematchinganalysis
AT houjun efficacyafterpreoperativecapecitabineandoxaliplatinxeloxversusdocetaxeloxaliplatinands1dosinpatientswithlocallyadvancedgastricadenocarcinomaapropensityscorematchinganalysis
AT jiyuan efficacyafterpreoperativecapecitabineandoxaliplatinxeloxversusdocetaxeloxaliplatinands1dosinpatientswithlocallyadvancedgastricadenocarcinomaapropensityscorematchinganalysis
AT sunyihong efficacyafterpreoperativecapecitabineandoxaliplatinxeloxversusdocetaxeloxaliplatinands1dosinpatientswithlocallyadvancedgastricadenocarcinomaapropensityscorematchinganalysis
AT shenzhenbin efficacyafterpreoperativecapecitabineandoxaliplatinxeloxversusdocetaxeloxaliplatinands1dosinpatientswithlocallyadvancedgastricadenocarcinomaapropensityscorematchinganalysis
AT liufenglin efficacyafterpreoperativecapecitabineandoxaliplatinxeloxversusdocetaxeloxaliplatinands1dosinpatientswithlocallyadvancedgastricadenocarcinomaapropensityscorematchinganalysis
AT liutianshu efficacyafterpreoperativecapecitabineandoxaliplatinxeloxversusdocetaxeloxaliplatinands1dosinpatientswithlocallyadvancedgastricadenocarcinomaapropensityscorematchinganalysis